Biotech Stocks: Amgen Up Due To Positive Phase III Data
Amgen Inc (AMGN) was up almost 3% on encouraging top-line data from a phase III study on its biosimilar candidate, ABP 501. The randomized, double-blind, active-controlled study compared the safety and efficacy of ABP 501 to AbbVie Inc’s (ABBV) Humira in adults suffering from moderate-to-severe plaque psoriasis. The study met its primary endpoint of Psoriasis Area and Severity Index (PASI) percent improvement from baseline at … Continue reading Biotech Stocks: Amgen Up Due To Positive Phase III Data